A worldwide leader in influenza prevention announced the publication of new real-world evidence (RWE) that demonstrated an MF59® adjuvanted, trivalent influenza vaccine (aTIV) was more effective than a standard-dose, non-adjuvanted trivalent seasonal vaccine in preventing influenza-related medical office visits and hospitalizations in seniors during the 2017-2018 influenza season in the USA.
Adding MF59® adjuvant to an influenza vaccine is designed to enhance the immune response to the influenza strains contained in the vaccine in adults 65 years and older.
Read More
